Eli Lilly and Co (LLY) Wins In Alimta Patent Case After Court Rules In Its Favor
Eli Lilly and Co (NYSE:LLY) has won a patent case in respect of the company’s Alimta cancer drug in the federal court. The company filed a patent infringement case against the Israel-based Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)’s unit. Predictably, the Israeli firm expressed its disappointment over the judgment and disclosed that its options are open to appeal the case.
Eli Lilly and Co (NYSE:LLY) pointed out the court ruling saying that generic products planned by the unit of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) will infringe the patents of the American firm in relation to their blockbuster cancer drug, Alimta.
The patent covered the Alimta administration to patients with a vitamin regimen and provided the protection of intellectual property until May 2022. That offered the exclusivity for Alimta in the United States market until then. Therefore, there was no point in enabling generic competition in the next two years’ time when a separate patent expires.
Earlier, the court gave a ruling in March last year. According to that ruling, the court upheld the earlier validity of the vitamin regimen patent that Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) was ready to challenge.
Eli Lilly and Co (NYSE:LLY)’s SVP and general counsel, Michael Harrington, said that the company was pleased with the ruling of the District Court on its Alimta. He was also pleased that the court found that the vitamin regimen patent was infringed by Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA).
The American firm’s SVP said that the company’s scientific research in support of the vitamin regimen patent warranted intellectual property protection. He said that the drug-maker will continue to stress the importance of protection of intellectual property rights as an important one to the biopharmaceutical industry, as well as, the patients that the industry serves. Eli Lilly and Co (NYSE:LLY) believes that the move would get the support for the next generation development of innovative medicines to unmet medical needs treatment.
Latest posts by Viraj Shah (see all)
- Tesla Motors Inc (NASDAQ:TSLA)’s Elon Musk Is Going After Semi Truck Industry - November 17, 2017 04:37 AM PDT
- Tesla Motors Inc (NASDAQ:TSLA) Is Not “Hotbed for Racist Behavior” - November 15, 2017 06:58 AM PDT
- Nikola Tesla and Tesla Motors Inc (TSLA) – The Past & Future of the World You Cannot Ignore- Part 1 - May 15, 2017 05:11 AM PDT